Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used.